MICHAEL GRAVES
Interim Principal Executive Officer
-
Michael Graves Interim Executive Chairman of the Board
Interim Principal Executive OfficerMike has served as a member of Eagle’s board of directors since 2013. Mike is Chairman of the board of directors of Nanocopoeia, Inc., and a member of the board of directors of RiboCor, Inc. Mike has a wide variety of pharmaceutical industry experience including his position as CEO and President of Paddock Laboratories, Inc., and multiple leadership positions leading to President of the Generic Products Division at Par Pharmaceutical from 1998 to 2006.
STEVEN RATOFF
Interim Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
-
Steven Ratoff Interim Chief Financial Officer
Principal Financial Officer
Principal Accounting OfficerSteve has served as a member of our board of directors since Eagle’s inception in 2007. From 2010, he has served as President and Chief Executive Officer of NovaDel Pharma, Inc., filling a number of executive positions since joining their board of directors in 2005, and is currently serving as its Chairman. Prior to NovaDel, Steve held various executive positions with Cima Labs, Inc., MacroMed, Inc., and Brown-Forman Corporation. In 2004, Steve began his ongoing tenure as a venture partner of ProQuest Investments.
DANIEL O’CONNOR
Chief Strategy Officer
Head of Corporate Development
-
Daniel O’Connor Chief Strategy Officer
Head of Corporate DevelopmentDan is our Chief Strategy Officer and Head of Corporate Development. Dan served as Finance Director from 2011 to May 2013, and has held multiple roles at Eagle during his tenure.
Prior to joining Eagle in 2007, Dan held a variety of management positions, such as Senior Analyst at Ethicon (a Johnson & Johnson Company subsidiary) and Lead Finance Liaison throughout Ethicon’s joint venture with Omrix Biopharmaceuticals. Dan additionally held several finance positions at Ranbaxy Pharmaceuticals Inc. (a wholly owned subsidiary of Ranbaxy Inc.), which markets generic products in the US.
Dan holds a BS in business administration from West Virginia University and an MBA from Rutgers University.
DEBRA HUSSAIN
Head of Commercial for Acute Care/Hospital
-
Debra Hussain Head of Commercial for Acute Care/Hospital
Debra joined Eagle as part of Eagle’s 2022 acquisition of Acacia Pharma with 25 years of pharmaceutical industry experience. As Chief Commercial Officer for Acacia, Debra had responsibility for BARHEMSYS® and BYFAVO®. Prior to Acacia, Debra spent 22 years at Eli Lilly and Company in positions of increasing responsibility, where she led the U.S. launches of multiple products. Debra has extensive experience in hospital-based sales and marketing across cardiovascular, urology, diabetes, neuroscience, osteoporosis, and critical care/anesthesia specialties.
Debra holds a B.S. from the University of Wisconsin-Milwaukee and a Master’s degree in Audiology from Memphis State University.
REED McCLUNG
Executive Vice President,
Oncology Business Development
-
Reed McClung Executive Vice President,
Oncology Business DevelopmentReed joined Eagle with more than 30 years of commercial experience and 25 years of pharmaceutical leadership across multiple commercial functions. His oncology/hematology experience spans 16+ years with Novartis, Celgene, and Bristol-Myers Squibb (BMS). Prior to joining Eagle, Reed led the $12B multiple myeloma franchise at Celgene/BMS. Prior to Celgene, Reed spent 13 years at Novartis in positions of increasing responsibility in both Canada and the U.S.
Reed earned his B.S. in biology from Mount Allison University, NB, Canada.
MICHAEL GRAVES
Interim Executive Chairman of the Board, Interim Principal Executive Officer
-
Michael Graves Interim Executive Chairman of the Board
Interim Principal Executive OfficerMike has served as a member of Eagle’s board of directors since 2013. Mike is Chairman of the board of directors of Nanocopoeia, Inc., and a member of the board of directors of RiboCor, Inc. Mike has a wide variety of pharmaceutical industry experience including his position as CEO and President of Paddock Laboratories, Inc., and multiple leadership positions leading to President of the Generic Products Division at Par Pharmaceutical from 1998 to 2006.
ROBERT L. GLENNING
Board Member,Compensation Committee Chair, Audit Committee, Nominating
and Corporate Governance Committee
-
Robert L. Glenning Board Member
Audit Committee Chair
Nominating and Corporate Governance CommitteeBob has over 30 years of experience in the healthcare industry and currently serves as President of the Financial Services and Information Technology Divisions and CFO at Hackensack Meridian Health, the most comprehensive healthcare delivery network in the state of New Jersey. He previously served as Executive Vice President and CFO of Hackensack University Health Network. From 2002 to 2007, Bob served as EVP and CFO of Kaleida Health, Inc. Prior to Kaleida Health, he served as VP and CEO of Acute Care at Northeast Health and Albany Memorial Hospital. Robert began his career at PricewaterhouseCoopers.
RICHARD A. EDLIN, J.D.
Board Member, Nominating and Corporate Governance Committee Chair, Compesation Committee
-
Richard A. Edlin, J.D. Board Member
Audit Committee
Compensation Committee
Nominating and Corporate Governance Committee ChairRich is currently the Vice Chair, Chair of Litigation Practice in New York and the Business & Regulatory Financial Services Litigation Group, and a member of the Executive Committee of the law firm Greenberg Traurig, LLP.
Rich is a member of the Board of Trustees of the Urban Justice Center; a member of the Board of Directors for Judges and Lawyers Breast Cancer Alert (JALBCA); a member of the Board of Governors of Hackensack University Medical Center; a trustee of The Carnegie Council for Ethics in International Affairs; a member of the Board of Governors, American Friends of Tel Aviv University; a member of the Economic Club of New York; a fellow of the Litigation Council of America; and a trustee of SEEDS – Access Changes Everything, among other professional and community activities.
JENNIFER SIMPSON, PhD
Board Member, Audit Committee, Nominating and
Corporate Governance Committee
-
JENNIFER SIMPSON, PhD Board Member
Audit Committee
Compensation Committee Chair
Nominating and Corporate Governance Committee
Lead Independent Director of the BoardDr. Simpson is the President and CEO of Panbela Therapeutics as of July 2020. She previously served as President and CEO of Delcath, 2015-2020.
Prior to Delcath, Dr. Simpson served in positions of increasing responsibility at ImClone Systems (a subsidiary of Eli Lilly and Company), most recently as Vice President, Global Marketing, Oncology Brand Lead, where she was responsible for product commercialization activities and launch preparation for one of their late stage assets. Prior to ImClone, Dr. Simpson was Product Director, Oncology Therapeutics Marketing at Ortho Biotech (now Janssen Biotech), a Pennsylvania-based biotech focused on innovative solutions in immunology, oncology and nephrology.
Early in her career, she spent over a decade as a hematology/oncology nurse practitioner and educator. Dr. Simpson earned a Ph.D. in Epidemiology from the University of Pittsburgh, an M.S. in Nursing from the University of Rochester, and a B.S. in Nursing from the State University of New York at Buffalo.
LUCIANA BORIO, MD
Board Member, Nominating and Corporate Governance Committee, Strategic Clinical Development Committee Chair
-
Luciana Borio, MD Board Member
Compensation Committee
Nominating and Corporate Governance Committee
Strategic Clinical Development Committee ChairDr. Borio has served as Senior Vice President of In-Q-Tel, an independent strategic investment firm that supports the mission of the United States national security community, since 2019, and served as a member of President Biden’s Transition COVID-19 Advisory Board from November 2020 to January 2021. Dr. Borio also currently serves as a Senior Fellow for Global Health at the Council on Foreign Relations and on the Scientific Advisory Board of Codagenix, Inc. Previously, Dr. Borio served as Director, Medical and Biodefense Preparedness Policy, for the White House National Security Council from 2017 to 2019. Prior to that, Dr. Borio spent nearly ten years at the United States Food and Drug Administration in roles of increasing responsibility, serving as Acting Chief Scientist from 2015 to 2017, Assistant Commissioner for Counterterrorism Policy from 2010 to 2017, Director of the Office of Counterterrorism and Emerging Threats from 2010 to 2015 and Medical Officer from 2008 to 2010. Dr. Borio earned an M.D. with distinction from George Washington University School of Medicine and a B.S. in Zoology from George Washington University.
STEVEN RATOFF
Board Member
-
Steven Ratoff Interim Chief Financial Officer
Principal Financial Officer
Principal Accounting OfficerSteve has served as a member of our board of directors since Eagle’s inception in 2007. From 2010, he has served as President and Chief Executive Officer of NovaDel Pharma, Inc., filling a number of executive positions since joining their board of directors in 2005, and is currently serving as its Chairman. Prior to NovaDel, Steve held various executive positions with Cima Labs, Inc., MacroMed, Inc., and Brown-Forman Corporation. In 2004, Steve began his ongoing tenure as a venture partner of ProQuest Investments.
